NASDAQ:CMPX Compass Therapeutics (CMPX) Stock Price, News & Analysis $0.86 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$0.89 +0.03 (+3.89%) As of 06:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Compass Therapeutics Stock (NASDAQ:CMPX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Compass Therapeutics alerts:Sign Up Key Stats Today's Range$0.83▼$0.9850-Day Range$0.86▼$2.5352-Week Range$0.83▼$6.88Volume20.73 million shsAverage Volume5.99 million shsMarket Capitalization$154.28 millionP/E RatioN/ADividend YieldN/APrice Target$10.21Consensus RatingModerate Buy Company Overview Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for the treatment of cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving anti-tumor responses and addressing limitations associated with existing cancer treatments. Compass Therapeutics’ pipeline has included CTX-471, an investigational agonist antibody targeting CD137, also known as 4-1BB. The therapy is designed to stimulate immune cells involved in tumor recognition and destruction and has been investigated in combination with other immuno-oncology treatments. The company has also pursued additional antibody programs intended to modulate immune signaling and support the development of combination therapies. Headquartered in Boston, Massachusetts, Compass Therapeutics conducts research and development activities primarily in the United States. As a clinical-stage company, its programs remain under development and may require additional clinical testing and regulatory review before any product can be commercialized.AI Generated. May Contain Errors. Read More Compass Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreCMPX MarketRank™: Compass Therapeutics scored higher than 80% of companies evaluated by MarketBeat, and ranked 103rd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCompass Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 1 strong buy rating, 12 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialCompass Therapeutics has a consensus price target of $10.21, representing about 1,092.3% upside from its current price of $0.86.Amount of Analyst CoverageCompass Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Compass Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.47) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Therapeutics is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompass Therapeutics has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Compass Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.45% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 15.99, which indicates bearish sentiment.Change versus previous monthShort interest in Compass Therapeutics has recently increased by 2.11%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompass Therapeutics does not currently pay a dividend.Dividend GrowthCompass Therapeutics does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.89 News SentimentCompass Therapeutics has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Compass Therapeutics this week, compared to 4 articles on an average week.Search Interest12 people have searched for CMPX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat Follows6 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $21,250.00 in company stock, which represents 0.0138% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Compass Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $21,250.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders18.70% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Therapeutics' insider trading history. Receive CMPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMPX Stock News HeadlinesCompass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Consensus Price Target of $10.21October 4 at 2:15 AM | americanbankingnews.comCompass Therapeutics (NASDAQ:CMPX) CAO Neil Lerner Buys 20,000 Shares of StockOctober 3 at 5:52 AM | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 5 at 1:00 AM | Banyan Hill Publishing (Ad)Compass Therapeutics (NASDAQ:CMPX) Stock: Insider Neil Lerner Purchases 20,000 SharesOctober 3 at 5:52 AM | insidertrades.comCompass Therapeutics consensus price target decreased by 33.73% to $6.03October 2 at 8:38 AM | msn.comWhat is HC Wainwright's Forecast for CMPX FY2027 Earnings?September 27, 2026 | americanbankingnews.comCompass Therapeutics (NASDAQ:CMPX) Stock Price Target Cut by Citizens JmpSeptember 25, 2026 | americanbankingnews.comCompass Therapeutics’ FDA setback raises concerns on Wall Street — HC Wainwright calls Tovecimig filing strategy ‘risky’September 24, 2026 | msn.comSee More Headlines CMPX Stock Analysis - Frequently Asked Questions How have CMPX shares performed this year? Compass Therapeutics' stock was trading at $5.37 at the beginning of the year. Since then, CMPX stock has decreased by 84.0% and is now trading at $0.8567. How were Compass Therapeutics' earnings last quarter? Compass Therapeutics, Inc. (NASDAQ:CMPX) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.02. When did Compass Therapeutics IPO? Compass Therapeutics (CMPX) raised $50 million in an initial public offering on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager. How do I buy shares of Compass Therapeutics? Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compass Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Alphabet (GOOG). Company Calendar Last Earnings8/06/2026Today10/05/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CMPX's financial health is in the Red zone, according to TradeSmith. CMPX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CMPX CIK1738021 Webwww.compasstherapeutics.com Phone617-500-8099FaxN/AEmployees39Year Founded2014Price Target and Rating Average Price Target for Compass Therapeutics$10.21 High Price Target$30.00 Low Price Target$4.00 Potential Upside/Downside+1,092.3%Consensus RatingModerate Buy Rating Score (0-4)2.76 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.71% Return on Assets-34.72% Debt Debt-to-Equity RatioN/A Current Ratio11.22 Quick Ratio11.22 Sales & Book Value Annual Sales$850 thousand Price / Sales181.51 Cash FlowN/A Price / Cash FlowN/A Book Value$1.11 per share Price / Book0.77Miscellaneous Outstanding Shares180,090,000Free Float146,412,000Market Cap$154.28 million OptionableNot Optionable Beta1.02 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CMPX) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
